Startups
OnKure is committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of #cancer.
Overview
Location
United States, Colorado, Boulder
Employees
11-50
Total raised
$7M
Founded date
2011
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 13
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 6, 2026 | US filings for jobless benefits rise to 199,000 last week, but layoffs remain historically low | Getting your Trinity Audio player ready... By MICHELLE CHAPMAN, AP Business Writer The number of Americans applying for unemployment benefits rose last week but layoffs remain in the historically healthy range of the past few years. U.S. fi... |
| Aug 6, 2026 | US stocks edge lower as oil prices rise and more earnings reports roll in | Getting your Trinity Audio player ready... By DAMIAN J. TROISE, AP Business Writer NEW YORK (AP) — Stocks edged further away from their recent records on Thursday as Wall Street faced pressure from rising oil prices and mixed company earnin... |
| Oct 7, 2024 | Business | Boulder’s OnKure goes public with merger; key drug trial underway | OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a merger that takes OnKure public and injects $65 million into the company as it moves through a key trial for its leading bre... |
| Oct 4, 2024 | OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million | -- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer -- On track to announce early clinical data for its lead program, OKI-219, in Q4... |
| Oct 4, 2024 | OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million | -- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer -- On track to announce early clinical data for its lead program, OKI-219, in Q4... |
| Dec 20, 2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry. While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a... |
| May 23, 2023 | OnKure Therapeutics Announces $54 Million Series C Financing | |
| May 23, 2023 | Business Business | OnKure closes Series C at $54M | BOULDER — OnKure Inc. a precision oncology company, has closed a $54 million Series C financing round, short of what it had hoped would be a $60 million drive. The financing was led by Surveyor Capital (a Citadel company) with participation... |
| May 23, 2023 | OnKure Therapeutics Announces $54 Million Series C Financing | Proceeds to fund the advancement of the Company’s robust pipeline of potentially best-in-class candidates, particularly lead discovery program, OKI-219, a selective PI3K alpha H1047R inhibitor /EIN News/ -- BOULDER, Colorado, May 23, 2023 (... |
Show more
Reviews 0
FAQ about OnKure Therapeutics
When was OnKure Therapeutics founded?
OnKure Therapeutics was founded in 2011.
How much funding has OnKure Therapeutics raised?
OnKure Therapeutics has raised $7M in total across 1 funding round.
What has the press written about OnKure Therapeutics?
Parsers VC has collected 13 articles mentioning OnKure Therapeutics, among them “US filings for jobless benefits rise to 199,000 last week, but layoffs remain historically low” (Aug 6, 2026) and “US stocks edge lower as oil prices rise and more earnings reports roll in” (Aug 6, 2026).
Is OnKure Therapeutics still active?
OnKure Therapeutics is probably closed: its latest activity on Parsers VC dates from Aug 6, 2026.